Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537282 | 0.84 | KMT2A (0.43) | DYRK1AHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL11161159 | 0.80 | ALDH1A1 (0.49) | DYRK1AHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL11161113 | 0.77 | KMO (0.48) | DYRK1AHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL1970012 | 0.75 | RAB9A (0.44) | HPGDALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL8213406 | 0.75 | DYRK1A (0.60) | DYRK1AHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL1000301 | 0.75 | DAO (0.50) | HPGDALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6988092 | 0.72 | DYRK1A (0.62) | DYRK1AHPGDALDH1A1KMT2AKDM4E | |
| SCHEMBL17002554 | 0.72 | MEN1 (0.48) | HPGDALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL17362093 | 0.72 | ACLY (0.42) | HPGDALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL7909779 | 0.71 | ALDH1A1 (0.44) | HPGDALDH1A1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-107074828-B | Compounds and compositions as RAF kinase inhibitors | 诺华股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| CN-107074828-A | Compounds and compositions as raf kinase inhibitors | 诺华股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | DYRK1A 333/4885HPGD 2531/4885ALDH1A1 1859/4885 |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | DYRK1A 820/4885HPGD 2793/4885ALDH1A1 2115/4885 |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | BRAF, RAF1, ARAF | DYRK1A 820/4885HPGD 2793/4885ALDH1A1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.